Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM et al..  2018.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.. Nat Immunol. 19(1):76-84.

Escorcia FE, Postow MA, Barker CA.  2017.  Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.. Cancer J. 23(1):32-39.

Zloza A, A Palucka K, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA et al..  2017.  Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.. J Immunother Cancer. 5(1):77.

Hurwitz ME, Sokhn J, Petrylak DP.  2016.  Cancer immunotherapy: new applications in urologic oncology.. Curr Opin Urol. 26(6):535-42.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM et al..  2016.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.. Nat Med. 22(12):1402-1410.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D et al..  2016.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.. Cancer Immunol Res. 4(11):936-947.

Dasoveanu DC, Shipman WD, Chia JJ, Chyou S, Lu TT.  2016.  Regulation of Lymph Node Vascular-Stromal Compartment by Dendritic Cells.. Trends Immunol. 37(11):764-777.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A et al..  2016.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.. Genome Biol. 17(1):231.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT et al..  2015.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.. Cancer Cell. 27(4):489-501.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.

Jain A, Kovacs JA, Nelson DL, Migueles SA, Pittaluga S, Fanslow W, Fan X, Wong DW, Massey J, Hornung R et al..  2011.  Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand.. Blood. 118(14):3811-7.